ArticleMolecular nutrition & food research2026
Bee Bread Protects Small Intestinal Mucosa and Modulates Local Redox Responses in Streptozotocin-Induced Diabetic Rats.
Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bee Bread (BB), a fermented bee product rich in antioxidant compounds, exerts protective effects against diabetes-associated small intestinal damage. This study investigated the effects of BB on small intestinal morphology, mucosal integrity, and antioxidant enzyme activity in streptozotocin (STZ)-induced diabetic rats. Forty Wistar albino rats were randomly divided into five groups: control, sham (50 mg/kg sodium citrate), diabetes (DM; 50 mg/kg STZ), BB (100 mg/kg), and Diabetes + Bee Bread (DM+BB). After 15 days, intestinal tissues were examined using histopathological, immunohistochemical (IHC), and scanning electron microscopy (SEM) analyses. Diabetic rats exhibited hyperglycemia (363.63 ± 14.64 mg/dL vs. 97.25 ± 2.71 mg/dL in controls at day 15; p < 0.001), weight loss, villus elongation, epithelial desquamation, and mucosal disorganization. BB supplementation reduced blood glucose levels (approximately 15%-16% in the DM+BB group), attenuated weight loss, and preserved small intestinal architecture, with significant differences in villus length among groups (p < 0.05). Mn-SOD immunoreactivity showed no significant differences among groups (p > 0.05), although redistribution was observed in diabetic tissues. CAT immunoreactivity remained weak and unchanged across groups. SEM analysis confirmed improved villus architecture and preserved goblet cell morphology following BB treatment. BB attenuated diabetes-induced small intestinal injury and preserved intestinal mucosal architecture, findings that may be associated with localized adaptive redox responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.